TAMEing ADPKD with metformin: safe and effective?

Abstract

The biguanide metformin has been safely and widely used in the treatment of type 2 diabetes mellitus for decades. Preclinical studies have suggested that it may have a role in slowing disease progression in autosomal dominant polycystic kidney disease. In this issue, Perrone et al. report results from the Trial of Administration of Metformin in PKD (TAME PKD) study, a phase 2 randomized controlled trial investigating the safety and tolerability of metformin in patients in the early stages of autosomal dominant polycystic kidney disease. We discuss the implications of these findings and how they relate to a major phase 3 trial in autosomal dominant polycystic kidney disease that will start later in 2021.

• Authors: Albert C M Ong, Ron T Gansevoort
• Journal: Kidney international (Kidney Int) Vol. 100 Issue 3 Pg. 513-515 (09 2021) ISSN: 1523-1755 [Electronic] United States
• PMID: 34420660 (Publication Type: Journal Article, Comment)
• Copyright: Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.

Chemical References

• Hypoglycemic Agents
• Metformin

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Humans
• Hypoglycemic Agents (adverse effects)
• Metformin (adverse effects)
• Polycystic Kidney, Autosomal Dominant (drug therapy)
• Research Design